According to a new study published by the British Medical Journal, anticoagulant drugs significantly help prevent the risk of death from the CCP (Chinese Communist Party) Virus (COVID-19).

The study patients were treated with heparin, an injected anticoagulant produced by generic drug manufacturers such as Teva Pharmaceutical Industries Ltd.

As reported in the medical journal Medical Xpress, the team of researchers from the United Kingdom and the United States wanted to estimate prophylactic anticoagulants’ effect on the risk of death and severe bleeding in patients admitted to the hospital with symptoms of the CCP Virus.

The findings were based on data obtained by the U.S. Department of Veterans Affairs for 4,297 patients (average age 68 years, 93% male) hospitalized with the virus between March 1 and July 31, 2020.

The study considered other potentially influential factors such as age, ethnicity, underlying conditions, medication history, weight, and smoking. The researchers followed these patients to determine whether they died or developed severe bleeding within 30 days of hospitalization.

A total of 3,627 patients (84.4%) received prophylactic anticoagulation therapy within 24 hours of admission, then some 622 deaths (14.5%) were reported within 30 days.

At 30 days, 14.3% of patients who received prophylactic anticoagulation within 24 hours of admission died, compared with 18.7% of patients who died but did not receive the treatment, equivalent to a relative risk reduction of up to 34% and an absolute risk reduction of 4.4%, according to Medical Xpress.

Researchers have been trying to find ways to use low-cost drugs for critically ill patients with the CCP Virus in the face of the ineffectiveness of some treatments.

According to Newsmax, one that has so far proven successful is dexamethasone, a steroid that has been shown to reduce the risk of death in one-third of patients on ventilators.

Some CCP Virus deaths result from blood clots in major veins and arteries. In addition to preventing blood clot formation, anticoagulants have anti-inflammatory and antiviral properties. As such, they should be effective against the CCP Virus. However, previous studies have not shown conclusive results.

Clinical trials are currently underway with prophylactic anticoagulants to see if they work as a treatment against the CCP Virus. The researchers maintain that the findings provide evidence to support their use among hospitalized patients.